The comparison of factors according to the development of HCC showed that older age (p = 0.05), lower HCV RNA levels (p < 0.001), higher alanine aminotransferase (ALT) level (p < 0.001), AST level (p < 0.001), γGTP level (p = 0.02), and lower platelet count (p < 0.001) were observed at the baseline of patients who developed HCC after treatment with DAAs (Table 3). The gene discussed is GPT; the disease is hepatocellular carcinoma.